tetano
Editor, Senior Moderator
J Infect Dev Ctries
. 2025 Mar 31;19(3):353-361.
doi: 10.3855/jidc.18381. Cumulative seroprevalence of SARS-CoV-2 antibodies among blood donors in Burkina Faso, April 2022
Salam Sawadogo[SUP] 1 [/SUP], Yacouba Diallo[SUP] 1 [/SUP], Koumpingnin Nebie[SUP] 1 [/SUP], Bertrand Ivlabèhirè Meda[SUP] 2 [/SUP], Corneille Ydriss Djerma[SUP] 3 [/SUP], Georges Pengdwendé Ouedraogo[SUP] 4 [/SUP], Donatien Kima[SUP] 1 [/SUP], Serge Mamadou Sawadogo[SUP] 5 [/SUP], Amadou Kafando[SUP] 6 [/SUP], Sinaré Coulibaly[SUP] 7 [/SUP], Bachirou Cheickh Ashmed Nana[SUP] 8 [/SUP], Dieudonné Yetema Yonli[SUP] 8 [/SUP], Martin Ouedraogo[SUP] 9 [/SUP], Anita Pierrette Siritie[SUP] 4 [/SUP], Sylvie Zida[SUP] 2 [/SUP], Charlemagne Sanhitouo Dabire[SUP] 2 [/SUP], Rakiatou Traore[SUP] 10 [/SUP], Kadidiatou Aïna Konate[SUP] 11 [/SUP], Anita Benao[SUP] 7 [/SUP], Seimbou Zalla[SUP] 12 [/SUP], Sonia Sontie[SUP] 12 [/SUP], Veronique Deneys[SUP] 13 [/SUP], Eléonore Kafando[SUP] 1 [/SUP], Gautier Henri Ouedraogo[SUP] 2 [/SUP]
Affiliations
Introduction: In Sub-Saharan Africa, the true extent of the COVID-19 pandemic is not known due to the low number of tests performed and the large proportion of asymptomatic cases in the populations. This was a seroprevalence study of SARS-CoV-2 antibodies in blood donors to assess the extent of virus circulation in Burkina Faso.
Methodology: It was a cross-sectional study that included unpaid blood donors between March and April 2022. A rapid diagnostic test was used to screen SARS-CoV-2 antibodies in donors' plasma. Adjustment was made based on the performance of the test evaluated in a national quality control.
Results: A total of 3,084 blood donors were recruited, of whom 58.7% were male and 59.8% were from urban areas. The mean age was 22.9 ± 5.8 years, with donors aged 20 to 29 years accounting for 64.2%. The adjusted seroprevalence was 87.2%; 95% CI (86.4- 87.9). There was no difference in SARS-CoV-2 seropositivity between men and women, and between urban and rural areas. Donors aged 30-39 years had 0.5-fold lower odds of having SARS-CoV-2 antibodies than those under 20. Similarly, compared to Bobo-Dioulasso, blood donors from the Dédougou, Fada N'Gourma, and Koudougou centres had 0.5, 0.2, and 0.5 times lower odds of having SARS-CoV-2 antibodies, respectively.
Conclusions: The study indicates a high population exposure to SARS-CoV-2, in contrast with the official reports from the national surveillance system. It underscores the need to strengthen surveillance and public health interventions both in urban and rural areas.
Keywords: Burkina Faso; COVID-19; SARS-CoV-2; antibodies; blood donors; seroprevalence.
. 2025 Mar 31;19(3):353-361.
doi: 10.3855/jidc.18381. Cumulative seroprevalence of SARS-CoV-2 antibodies among blood donors in Burkina Faso, April 2022
Salam Sawadogo[SUP] 1 [/SUP], Yacouba Diallo[SUP] 1 [/SUP], Koumpingnin Nebie[SUP] 1 [/SUP], Bertrand Ivlabèhirè Meda[SUP] 2 [/SUP], Corneille Ydriss Djerma[SUP] 3 [/SUP], Georges Pengdwendé Ouedraogo[SUP] 4 [/SUP], Donatien Kima[SUP] 1 [/SUP], Serge Mamadou Sawadogo[SUP] 5 [/SUP], Amadou Kafando[SUP] 6 [/SUP], Sinaré Coulibaly[SUP] 7 [/SUP], Bachirou Cheickh Ashmed Nana[SUP] 8 [/SUP], Dieudonné Yetema Yonli[SUP] 8 [/SUP], Martin Ouedraogo[SUP] 9 [/SUP], Anita Pierrette Siritie[SUP] 4 [/SUP], Sylvie Zida[SUP] 2 [/SUP], Charlemagne Sanhitouo Dabire[SUP] 2 [/SUP], Rakiatou Traore[SUP] 10 [/SUP], Kadidiatou Aïna Konate[SUP] 11 [/SUP], Anita Benao[SUP] 7 [/SUP], Seimbou Zalla[SUP] 12 [/SUP], Sonia Sontie[SUP] 12 [/SUP], Veronique Deneys[SUP] 13 [/SUP], Eléonore Kafando[SUP] 1 [/SUP], Gautier Henri Ouedraogo[SUP] 2 [/SUP]
Affiliations
- PMID: 40168379
- DOI: 10.3855/jidc.18381
Introduction: In Sub-Saharan Africa, the true extent of the COVID-19 pandemic is not known due to the low number of tests performed and the large proportion of asymptomatic cases in the populations. This was a seroprevalence study of SARS-CoV-2 antibodies in blood donors to assess the extent of virus circulation in Burkina Faso.
Methodology: It was a cross-sectional study that included unpaid blood donors between March and April 2022. A rapid diagnostic test was used to screen SARS-CoV-2 antibodies in donors' plasma. Adjustment was made based on the performance of the test evaluated in a national quality control.
Results: A total of 3,084 blood donors were recruited, of whom 58.7% were male and 59.8% were from urban areas. The mean age was 22.9 ± 5.8 years, with donors aged 20 to 29 years accounting for 64.2%. The adjusted seroprevalence was 87.2%; 95% CI (86.4- 87.9). There was no difference in SARS-CoV-2 seropositivity between men and women, and between urban and rural areas. Donors aged 30-39 years had 0.5-fold lower odds of having SARS-CoV-2 antibodies than those under 20. Similarly, compared to Bobo-Dioulasso, blood donors from the Dédougou, Fada N'Gourma, and Koudougou centres had 0.5, 0.2, and 0.5 times lower odds of having SARS-CoV-2 antibodies, respectively.
Conclusions: The study indicates a high population exposure to SARS-CoV-2, in contrast with the official reports from the national surveillance system. It underscores the need to strengthen surveillance and public health interventions both in urban and rural areas.
Keywords: Burkina Faso; COVID-19; SARS-CoV-2; antibodies; blood donors; seroprevalence.